Issues in Pediatric Vaccine-preventable Diseases in Low- to Middle-income Countries

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2016 Jun 21

PMID 27322436

Citations 9

Authors

Ghassan Dbaibo

Vladimir Tatochenko

Peter Wutzler

Affiliations

Soon will be listed here.

Abstract

The highest burden of pediatric vaccine-preventable disease is found in developing nations where resource constraints pose the greatest challenge, impacting disease diagnosis and surveillance as well as the implementation of large scale vaccination programmes. In November 2012, a Working Group Meeting convened in Casablanca to describe and discuss the status with respect to 8 vaccine-preventable diseases (pertussis, pneumococcal disease, measles-mumps-rubella-varicella (MMRV), rotavirus and meningococcal meningitis) to identify and consider ways of overcoming obstacles to pediatric vaccine implementation. Experts from Europe, Russia, the Commonwealth of Independent States, the Middle East, Africa and South East Asia participated in the meeting. A range of region-specific needs and barriers to uptake were discussed. The aim of this article is to provide a summary of the ongoing status with respect to pediatric vaccine preventable disease in the countries represented, and the experts' opinions and recommendations with respect to pediatric vaccine implementation.

Citing Articles

Tunisian Pediatricians' Attitudes and Practices Toward COVID-19 Immunization and Other Vaccines.

Cherif I, Gharbi R, Kharroubi G, Affes W, Bettaieb J Int J Environ Res Public Health. 2025; 22(2).

PMID: 40003458 PMC: 11854911. DOI: 10.3390/ijerph22020233.

Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco.

Abouqal R, Beji M, Chakroun M, Marhoum El Filali K, Rammaoui J, Zaghden H Front Public Health. 2022; 10:903376.

PMID: 35844850 PMC: 9286557. DOI: 10.3389/fpubh.2022.903376.

Cost effectiveness and budget impact of universal varicella vaccination in Russia.

Marijam A, Safonova E, Scherbakov M, Shpeer E, Van Oorschot D, Rudakova A Hum Vaccin Immunother. 2022; 18(5):2045152.

PMID: 35258445 PMC: 9196720. DOI: 10.1080/21645515.2022.2045152.

Measles and mumps outbreaks in Lebanon: trends and links.

El Zarif T, Kassir M, Bizri N, Kassir G, Musharrafieh U, Bizri A BMC Infect Dis. 2020; 20(1):244.

PMID: 32216754 PMC: 7098136. DOI: 10.1186/s12879-020-04956-1.

The clinical and economic burden of varicella in the Middle East: a systematic literature review.

Al Kaabi N, Al Olama F, Al Qaseer M, Al Ubaidani I, Dinleyici E, Hayajneh W Hum Vaccin Immunother. 2019; 16(1):21-32.

PMID: 31373864 PMC: 7012098. DOI: 10.1080/21645515.2019.1638726.

References

Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor J, Cohen R . Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007; 370(9601):1757-63. DOI: 10.1016/S0140-6736(07)61744-9. View

Bayer O, Heininger U, Heiligensetzer C, von Kries R . Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine. 2007; 25(37-38):6655-60. DOI: 10.1016/j.vaccine.2007.07.010. View

Breiman R, Zaman K, Armah G, Sow S, Anh D, Victor J . Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine. 2012; 30 Suppl 1:A24-9. DOI: 10.1016/j.vaccine.2011.08.124. View

Ceyhan M, Anis S, Htun-Myint L, Pawinski R, Soriano-Gabarro M, Vyse A . Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention. Int J Infect Dis. 2012; 16(8):e574-82. DOI: 10.1016/j.ijid.2012.03.011. View

. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011; 86(47):521-39. View

Hammitt L, Ojal J, Bashraheil M, Morpeth S, Karani A, Habib A . Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. PLoS One. 2014; 9(1):e85459. PMC: 3897448. DOI: 10.1371/journal.pone.0085459. View

Patel M, Lopez-Collada V, Bulhoes M, De Oliveira L, Bautista Marquez A, Flannery B . Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011; 364(24):2283-92. DOI: 10.1056/NEJMoa1012952. View

Dayan G, Rubin S . Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?. Clin Infect Dis. 2008; 47(11):1458-67. DOI: 10.1086/591196. View

Chaves S, Gargiullo P, Zhang J, Civen R, Guris D, Mascola L . Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007; 356(11):1121-9. DOI: 10.1056/NEJMoa064040. View

10.

Desai R, Parashar U, Lopman B, De Oliveira L, Clark A, Sanderson C . Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America. Clin Infect Dis. 2012; 54(10):1397-405. DOI: 10.1093/cid/cis191. View

11.

Offit P . The future of rotavirus vaccines. Semin Pediatr Infect Dis. 2002; 13(3):190-5. DOI: 10.1053/spid.2002.125862. View

12.

Tregnaghi M, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A . Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med. 2014; 11(6):e1001657. PMC: 4043495. DOI: 10.1371/journal.pmed.1001657. View

13.

Vesikari T, Matson D, Dennehy P, Van Damme P, Santosham M, Rodriguez Z . Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006; 354(1):23-33. DOI: 10.1056/NEJMoa052664. View

14.

. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010; 85(40):385-400. View

15.

. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep. 1999; 48(43):1007. View

16.

Poolman J, Borrow R . Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011; 10(3):307-22. DOI: 10.1586/erv.11.8. View

17.

Heininger U, Seward J . Varicella. Lancet. 2006; 368(9544):1365-76. DOI: 10.1016/S0140-6736(06)69561-5. View

18.

Marin M, Guris D, Chaves S, Schmid S, Seward J . Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-4):1-40. View

19.

Parashar U, Hummelman E, Bresee J, Miller M, Glass R . Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003; 9(5):565-72. PMC: 2972763. DOI: 10.3201/eid0905.020562. View

20.

Madhi S, Cunliffe N, Steele D, Witte D, Kirsten M, Louw C . Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010; 362(4):289-98. DOI: 10.1056/NEJMoa0904797. View